相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach
Quintino G. D'Alessandris et al.
JOURNAL OF NEUROSURGICAL SCIENCES (2023)
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Aaron C. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults
Isabelle M. Germano et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults
Mateo Ziu et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
Congress of neurological surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods
Jeffrey J. Olson
JOURNAL OF NEURO-ONCOLOGY (2022)
Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults
Hayes H. Patrick et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma
Tetsuya Yamada et al.
JOURNAL OF NEUROSURGERY (2021)
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies
Michael T. C. Poon et al.
BMC CANCER (2021)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Cristina Birzu et al.
CANCERS (2021)
Putting Proteomics Into Immunotherapy for Glioblastoma
Liangyu Chen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Current Immunotherapies for Glioblastoma Multiforme
Boyuan Huang et al.
FRONTIERS IN IMMUNOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
Elisabete Cruz Da Silva et al.
CANCERS (2021)
The prognosis of glioblastoma: a large, multifactorial study
Chen Luo et al.
BRITISH JOURNAL OF NEUROSURGERY (2021)
Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
Guido Giordano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
Giuseppe Lombardi et al.
CANCERS (2021)
Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
Ruichao Chai et al.
CANCER BIOLOGY & MEDICINE (2021)
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin van den Bent et al.
NEURO-ONCOLOGY (2020)
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Dima A. Sabbah et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
Survival after reoperation for recurrent glioblastoma
Royce W. Woodroffe et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2020)
Stereotactic Radiotherapy in Recurrent Glioblastoma: A Valid Salvage Treatment Option
Gokhan Yaprak et al.
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY (2020)
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Bhavesh K. Ahir et al.
MOLECULAR NEUROBIOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Glioblastoma Immune Landscape and the Potential of New Immunotherapies
Thomas Daubon et al.
FRONTIERS IN IMMUNOLOGY (2020)
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma
Andrew S. Chi et al.
JCO PRECISION ONCOLOGY (2020)
Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment
Francesca A. Carrieri et al.
FRONTIERS IN ONCOLOGY (2020)
Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Therapy for glioblastoma: is it working?
Edward D. Zanders et al.
DRUG DISCOVERY TODAY (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
Guangrong Lu et al.
FRONTIERS IN NEUROLOGY (2019)
Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts
Masamichi Takahashi et al.
CANCER SCIENCE (2019)
Targeted Therapies for the Treatment of Glioblastoma in Adults
Ding Fang Chuang et al.
CURRENT ONCOLOGY REPORTS (2019)
Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
Emma Boydell et al.
CANCERS (2019)
The Role of Checkpoint Inhibitors in Glioblastoma
Kunal Desai et al.
TARGETED ONCOLOGY (2019)
Immune Resistance and EGFR Antagonists in Colorectal Cancer
Guido Giordano et al.
CANCERS (2019)
Carbon ion radiotherapy in the treatment of gliomas: a review
Timothy D. Malouff et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Longitudinal molecular trajectories of diffuse glioma in adults
Floris P. Barthel et al.
NATURE (2019)
Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept
E. Braeutigam et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Bryan D. Choi et al.
CLINICAL CANCER RESEARCH (2019)
Re-irradiation in elderly patients with glioblastoma: a single institution experience
Christoph Straube et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
E. Antonio Chiocca et al.
NEURO-ONCOLOGY (2019)
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials
Maryam Moradi Binabaj et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing
Diana Cantero et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients A phase I/II trial
Alfredo Marinelli et al.
MEDICINE (2018)
Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons
Bryan D. Choi et al.
NEUROSURGICAL FOCUS (2018)
Comparison of glioblastoma (GBM) molecular classification methods
Eunjee Lee et al.
SEMINARS IN CANCER BIOLOGY (2018)
Impact of resection on overall survival of recurrent Glioblastoma in elderly it patients
Jasmin Hager et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Martin J. van den Bent et al.
LANCET ONCOLOGY (2018)
Relapsed glioblastomas respond to regorafenib
Peter Sidaway
Nature Reviews Clinical Oncology (2018)
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma
K. Zwirner et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume
Andrea Di Cristofori et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma Clinical Trial/Experimental Study
Lei Wang et al.
MEDICINE (2017)
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
Tiffany R. Hodges et al.
NEURO-ONCOLOGY (2017)
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
Tomokazu Aoki et al.
NEUROLOGIA MEDICO-CHIRURGICA (2017)
Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
Eiichi Ishikawa et al.
NEUROLOGIA MEDICO-CHIRURGICA (2017)
Reoperation for Recurrent Glioblastoma Multiforme
Adam M. Robin et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications
Alba A. Brandes et al.
ONCOLOGIST (2017)
Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma
Johann Klein et al.
ONCOLOGY (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Re-irradiation after gross total resection of recurrent glioblastoma Spatial pattern of recurrence and a review of the literature as a basis for target volume definition
Christoph Straube et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2017)
Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
Xiaomin Liu et al.
ONCOTARGET (2017)
Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival
Juan Delgado-Fernandez et al.
WORLD NEUROSURGERY (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Glioblastoma targeted therapy: updated approaches from recent biological insights
M. Touat et al.
ANNALS OF ONCOLOGY (2017)
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Vivek Subbiah et al.
JCI INSIGHT (2017)
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
P. Perez-Segura et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Gaspar Reynes et al.
ANTI-CANCER DRUGS (2016)
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
Eric T. Wong et al.
BMC CANCER (2016)
Survival in glioblastoma: a review on the impact of treatment modalities
P. D. Delgado-Lopez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study
Giuseppe Lombardi et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial
Bogdana Suchorska et al.
NEURO-ONCOLOGY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma
S. B. M. D. Harrabi et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2016)
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
George Ansstas et al.
CASE REPORTS IN NEUROLOGY (2016)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Introduction: brain tumor immunotherapy
Michael Lim et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Matthias Preusser et al.
NATURE REVIEWS NEUROLOGY (2015)
Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis
Valentina Pinzi et al.
NEUROLOGICAL SCIENCES (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences
Barbara Heidenreich et al.
ONCOTARGET (2015)
The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma
Randy S. D'Amico et al.
WORLD NEUROSURGERY (2015)
Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: a single institution experience
Shaakir Hasan et al.
FRONTIERS IN ONCOLOGY (2015)
Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells
Hossein A. Hamed et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The role of cytoreductive surgery in the management of progressive glioblastoma
Timothy Charles Ryken et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Hypofractionated stereotactic reirradiation for recurrent glioblastoma
Gozde Yazici et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Residual tumor volume and patient survival following reoperation for recurrent glioblastoma
Raymund L. Yong et al.
JOURNAL OF NEUROSURGERY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
Seunggu J. Han et al.
NEURO-ONCOLOGY (2014)
Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study
Jeffrey Noah Greenspoon et al.
ONCOTARGETS AND THERAPY (2014)
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
Guido Giordano et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2014)
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
Patrick J. Killela et al.
ONCOTARGET (2014)
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Evanthia Galanis et al.
CLINICAL CANCER RESEARCH (2013)
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2013)
The influence of surgery on recurrence pattern of glioblastoma
Pasquale De Bonis et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2013)
IDH1 and IDH2 Mutations in Gliomas
Adam L. Cohen et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
Arnab Chakravarti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
Matteo Santoni et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Antonio Omuro et al.
NEURO-ONCOLOGY (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D. Norden et al.
NEURO-ONCOLOGY (2013)
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
Patrizia Ciammella et al.
RADIATION ONCOLOGY (2013)
Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme
Eleftherios Archavlis et al.
BMJ OPEN (2013)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
Enrico Franceschi et al.
NEURO-ONCOLOGY (2012)
Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
Aaron Michael Rulseh et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas
Po-Cheng Lin et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Hideho Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
Jennifer L. Clarke et al.
NEURO-ONCOLOGY (2011)
Surgery for Glioblastoma Multiforme: Striking a Balance
Raymund L. Yong et al.
WORLD NEUROSURGERY (2011)
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
Nabil Ahmed et al.
CLINICAL CANCER RESEARCH (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Benedikte Hasselbalch et al.
NEURO-ONCOLOGY (2010)
Recent Advances of Dendritic Cells (DCs)-Based Immunotherapy for Malignant Gliomas
Der-Yang Cho et al.
CELL TRANSPLANTATION (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
A microarray-based DNA methylation study of glioblastoma multiforme
Ramon Martinez et al.
EPIGENETICS (2009)
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Jennifer A. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
'Recurrent' glioblastoma multiforme, when should we reoperate?
Giuseppe M. V. Barbagallo et al.
BRITISH JOURNAL OF NEUROSURGERY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide
S. S. M. Ng et al.
CANCER GENE THERAPY (2007)
Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: recurrence or second primary tumor?
Krista A. Van Nifterik et al.
JOURNAL OF NEUROSURGERY (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination
Gentao Liu et al.
EXPERT REVIEW OF VACCINES (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines
ME Halatsch et al.
JOURNAL OF NEUROSURGERY (2004)
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
A Östman
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
分享论文
